See the DrugPatentWatch profile for zepbound
What FDA approvals do Zepbound and Mounjaro have?
Zepbound (tirzepatide) is approved for chronic weight management in adults with obesity or overweight with weight-related conditions, at doses up to 15 mg weekly.[1] Mounjaro (also tirzepatide) is approved for type 2 diabetes management, at doses up to 15 mg weekly.[1] Both are GLP-1/GIP receptor agonists from Eli Lilly, but Zepbound targets weight loss primarily, while Mounjaro focuses on blood sugar control.
How do their uses differ in practice?
Mounjaro treats diabetes by improving glycemic control, often alongside diet and exercise. Zepbound aids weight loss without a diabetes requirement, though doctors sometimes prescribe Mounjaro off-label for obesity due to similar effects on appetite and metabolism.[2] Clinical trials showed Zepbound users lost up to 21% body weight over 72 weeks, outperforming placebo; Mounjaro reduced A1C by up to 2.3% in diabetes patients.[1][3]
What's the pricing and access difference?
Both cost around $1,000-$1,300 monthly without insurance, but coverage varies: Medicare often covers Mounjaro for diabetes but not Zepbound for weight loss. Commercial plans may cover Zepbound more for obesity. Single-dose vials help reduce costs for self-pay patients.[4]
Do they have the same side effects?
Side effects overlap—nausea (up to 36%), diarrhea, vomiting, constipation, and injection-site reactions—due to identical active ingredients. Zepbound trials reported slightly higher gastrointestinal issues at max doses. Rare risks like thyroid tumors or pancreatitis apply to both; monitor gallbladder issues.[1][3]
Can you switch between them?
Yes, since they contain the same drug, switching is straightforward at equivalent doses (e.g., 5 mg Mounjaro to 5 mg Zepbound). Prescribing depends on indication: Mounjaro for diabetes, Zepbound for weight loss. Compounding versions exist amid shortages, but FDA warns of risks.[2][5]
Who makes them and what's the supply situation?
Eli Lilly manufactures both. Mounjaro faced shortages in 2023-2024 due to demand; Zepbound availability improved faster with new pens. No generic or biosimilar versions yet; patents extend into the 2030s.[1][6]
Sources:
[1] FDA Labels for Mounjaro and Zepbound
[2] Eli Lilly Product Information
[3] SURMOUNT and SURPASS Trial Data
[4] GoodRx Pricing Comparison
[5] FDA Shortage Tracker
[6] DrugPatentWatch.com - Tirzepatide Patents